Format

Send to

Choose Destination
Sci Rep. 2017 Feb 23;7:43201. doi: 10.1038/srep43201.

Classification of idiopathic interstitial pneumonias using anti-myxovirus resistance-protein 1 autoantibody.

Author information

1
Department of Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita City, Osaka 565-0871, Japan.
2
AMED, CREST, Suita City, Osaka 565-0871, Japan.
3
Medical &Biological Laboratories Co., Ltd., Ina Laboratory, 1063-103 Terasawaoka, Ina City, Nagano 396-0002, Japan.
4
Department of Radiology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita City, Osaka 565-0871, Japan.
5
National Institutes of Biomedical Innovation, Health and Nutrition, 7-6-8 Saitoasagi, Ibaraki City, Osaka 567-0085, Japan.
6
National Hospital Organization Kinki-Chuo Chest Medical Center, 1180 Nagasone-Cho, Kita-Ku, Sakai City, Osaka 591-8555, Japan.
7
Office of Biostatistics and Data Management, National Cerebral and Cardiovascular Center, 5-7-1 Fujishirodai, Suita City, Osaka 565-8565, Japan.
8
National Hospital Organization Toneyama National Hospital, 5-1-1 Toneyama, Toyonaka City, Osaka 560-8552, Japan.
9
Department of Immunopathology, WPI Immunology Frontier Research Center, Osaka University, Yamadaoka 3-1, Suita City, Osaka 565-0871, Japan.
10
Department of Experimental Immunology, WPI Immunology Frontier Research Center, Osaka University, Yamadaoka 3-1, Suita City, Osaka 565-0871, Japan.

Abstract

Chronic fibrosing idiopathic interstitial pneumonia (IIP) can be divided into two main types: idiopathic pulmonary fibrosis (IPF), a steroid-resistant and progressive disease with a median survival of 2-3 years, and idiopathic non-specific interstitial pneumonia (INSIP), a steroid-sensitive and non-progressive autoimmune disease. Although the clinical courses of these two diseases differ, they may be difficult to distinguish at diagnosis. We performed a comprehensive analysis of serum autoantibodies from patients definitively diagnosed with IPF, INSIP, autoimmune pulmonary alveolar proteinosis, and sarcoidosis. We identified disease-specific autoantibodies and enriched KEGG pathways unique to each disease, and demonstrated that IPF and INSIP are serologically distinct. Furthermore, we discovered a new INSIP-specific autoantibody, anti-myxovirus resistance-1 (MX1) autoantibody. Patients positive for anti-MX1 autoantibody constituted 17.5% of all cases of chronic fibrosing IIPs. Notably, patients rarely simultaneously carried the anti-MX1 autoantibody and the anti-aminoacyl-transfer RNA synthetase autoantibody, which is common in chronic fibrosing IIPs. Because MX1 is one of the most important interferon-inducible anti-viral genes, we have not only identified a new diagnostic autoantibody of INSIP but also obtained new insight into the pathology of INSIP, which may be associated with viral infection and autoimmunity.

PMID:
28230086
PMCID:
PMC5322336
DOI:
10.1038/srep43201
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center